Vanda Pharmaceuticals Inc. (VNDA) Position Lifted by Schwab Charles Investment Management Inc.
Schwab Charles Investment Management Inc. increased its holdings in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 3.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 460,869 shares of the biopharmaceutical company’s stock after acquiring an additional 16,183 shares during the quarter. Schwab Charles Investment Management Inc. owned about 1.03% of Vanda Pharmaceuticals worth $7,513,000 as of its most recent SEC filing.
Other hedge funds have also bought and sold shares of the company. Virginia Retirement Systems ET AL acquired a new position in Vanda Pharmaceuticals in the 1st quarter valued at $193,000. Dynamic Technology Lab Private Ltd acquired a new position in Vanda Pharmaceuticals in the 1st quarter valued at $196,000. American International Group Inc. grew its holdings in Vanda Pharmaceuticals by 7.1% in the 1st quarter. American International Group Inc. now owns 22,563 shares of the biopharmaceutical company’s stock valued at $316,000 after buying an additional 1,491 shares in the last quarter. Trexquant Investment LP acquired a new position in Vanda Pharmaceuticals in the 2nd quarter valued at $384,000. Finally, Perceptive Advisors LLC acquired a new position in Vanda Pharmaceuticals in the 1st quarter valued at $507,000. 86.49% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “Vanda Pharmaceuticals Inc. (VNDA) Position Lifted by Schwab Charles Investment Management Inc.” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.thecerbatgem.com/2017/10/08/vanda-pharmaceuticals-inc-vnda-position-lifted-by-schwab-charles-investment-management-inc.html.
A number of research analysts have commented on the company. Zacks Investment Research lowered Vanda Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday. Piper Jaffray Companies upped their price objective on Vanda Pharmaceuticals from $23.00 to $26.00 and gave the company an “overweight” rating in a report on Thursday, September 14th. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Vanda Pharmaceuticals in a report on Thursday, September 14th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Vanda Pharmaceuticals in a report on Tuesday, August 29th. Finally, BidaskClub raised Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, August 22nd. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $21.63.
Vanda Pharmaceuticals Inc. (VNDA) opened at 17.35 on Friday. The firm has a 50-day moving average price of $17.40 and a 200-day moving average price of $15.56. The firm’s market capitalization is $778.29 million. Vanda Pharmaceuticals Inc. has a one year low of $12.70 and a one year high of $18.99.
Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.21) by $0.18. Vanda Pharmaceuticals had a negative net margin of 6.54% and a negative return on equity of 7.85%. The business had revenue of $42.06 million for the quarter, compared to analyst estimates of $40.31 million. During the same period in the previous year, the company earned $0.01 earnings per share. The business’s revenue for the quarter was up 16.7% on a year-over-year basis. Analysts expect that Vanda Pharmaceuticals Inc. will post ($0.42) EPS for the current year.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Want to see what other hedge funds are holding VNDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA).
Receive News & Stock Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.